a b s t r a c t 3,7-Diazabicyclo[3.3.1]nonane is a naturally occurring scaffold interacting with nicotinic acetylcholine receptors (nAChRs). When one nitrogen of the 3,7-diazabicyclo[3.3.1]nonane scaffold was implemented in a carboxamide motif displaying a hydrogen bond acceptor (HBA) functionality, compounds with higher affinities and subtype selectivity for a4b2 ⁄ were obtained. The nature of the HBA system (carboxamide, sulfonamide, urea) had a strong impact on nAChR interaction. High affinity ligands for a4b2 ⁄ possessed small alkyl chains, small un-substituted hetero-aryl groups or para-substituted phenyl ring systems along with a carboxamide group. Electrophysiological responses of selected 3,7-diazabicyclo[3.3.1]nonane derivatives to Xenopus oocytes expressing various nAChR subtypes showed diverse activation profiles. Compounds with strongest agonistic profiles were obtained with small alkyl groups whereas a shift to partial agonism/antagonism was observed for aryl substituents.
Introduction
Nicotinic acetylcholine receptors (nAChRs) are ligand-gated excitatory cation channels and can form homomeric or heteromeric subtypes. [1] [2] [3] [4] Each nAChR complex is composed of a combination of five identical or different subunits (a1-a10, b1-b4, c, d and e) capable of forming a water-filled pore in the cell membrane. [1] [2] [3] [4] Stimulation of these receptors have an impact on membrane potential and the release of diverse neurotransmitters, which is often subtype specific and can vary across areas of a specific organ, for example, different brain areas. [1] [2] [3] [4] NAChRs have been proposed as potential drug targets for the treatment of various central nervous system (CNS) diseases. [5] [6] [7] For example, b2-containing nAChRs have a wide-spread expression in the brain and subunit combination with a4, a5, a6, and/or b3 are implemented in depression and addiction. [8] [9] [10] [11] The majority of nAChR ligands have been derived from very potent natural products displaying the important pharmacophoric features found in the neurotransmitter acetylcholine (ACh) 1. 6, 7, 12 Cation-p/HB forces along with HBA interactions corresponding to the charged/protonable nitrogen and, for example, carbonyl or heteroaryl moieties, respectively, are involved in the interaction with the receptors. [13] [14] [15] [16] [17] [18] (Di)azabicyclic octane and diazabicyclic nonane scaffold bearing compounds are the majority representing the nAChR pharmacopeia in the recent past. 6, 7 Among these bicyclic N-containing structural templates is 3,7-diazabicyclo[3.3.1]nonane. 6, 7 It is a naturally occuring scaffold also known as bispidine found, for example, in the nAChR ligand cytisine and sparteine, a sodium ion channel blocker. 19 3,7-Diazabicyclo[3.3.1]nonane derivatives have been the subject of considerable interest in the field of novel nAChR compounds, but also as, for example, antiarrhythmic drugs, opioid receptor ligands, and as multidentate ligands for organometallic compounds. [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] The most prominent 3,7-diazabicyclo[3.3.1]nonane compound interacting with nAChRs is the natural product cytisine 3 with high affinity for a4b2 ⁄ nAChR ( Fig. 1 ; Table 1) . 38, 39 Cytisine 3, its derivative 3-(pyridine-3-yl)-cytisine (3PC) 4, recently developed by us, and varenicline 5 (Chantix Ò , used for smoking cessation) ( Fig. 1) , derived from cytisine, have antidepressant-like effects in mice ( Fig. 1 ; Table 1 ). [40] [41] [42] [43] All three compounds possess high affinity and partial agonist functionality for the a4b2 ⁄ subtype to a various degree, but the rigid compounds cytisine 3 and varenicline 5 have limited subtype selectivity. [41] [42] [43] Since the intact cytisine template is limited in its synthetic access, chemical space, ADMET properties, affinity and functional selectivity profiles, we revisited the 3,7-diazabicyclo[3.3.1]nonane ring system (bispidine) as a nAChR ligand itself. This scaffold is synthetically easily accessible via double Mannich reaction and displays one pharmacophoric element. To explore the chemical space around this scaffold further, 3,7-diazabicyclo[3.3.1]nonane was attached to a variety of aromatic and non-aromatic substitutents via different HBA motifs. In contrast to cytisine 3 where the HBA system (pyridone) is fused to the 3,7-diazabicyclo[3.3.1]nonane scaffold, the HBA motifs of the synthesized derivatives are acyclic, thus compounds display higher flexibility. A similar approach, but limited to a carboxamide HBA motif and limited substitution pattern have been done by Targacept, Inc. which resulted in the development of the a4b2 agonist TC-6683/AZD1446 bearing the diazabicyclic system 3,7-diazabicyclo[3.3.0]octane. [27] [28] [29] This compound showed positive effects on a rodent model for working memory. Our extensive study around the bispidine scaffold started with bispidine (3,7-diazabicyclo[3.3.1] nonane) itself which was tested for affinities at different nAChRs and functional properties. Simple 3,7-diazabicyclo[3.3.1]nonane compounds with different HBA systems, like carboxamides, sulfonamides and urea groups attached to simple alkyl or (heter)aryl substituents were synthesized ( Fig. 2) to get more insight into structure activity relationships for nAChRs. Compounds were tested for their affinities, and selected candidates displaying nAChR affinity in the nanomolar range were additionally evaluated for their functionality in Xenopus oocyte experiments.
Results and discussion

Chemistry
The 3,7-diazabicyclo[3.3.1]nonane (bispidine) scaffold was synthesized according to a previously published method. 24, 25, [46] [47] [48] 
N-
Benzyl-N 0 -tboc-bispidinone 10 was obtained by a double Mannich reaction from commercially available tert-butyl 4-oxopiperidine carboxylate 9, benzylamine, and paraformaldehyde. It was purified by flash chromatography.
The reduction of the carbonyl functionality of N-benzyl-N 0 -tbocbispidinone 10 was attempted by several published methods but in our hands none of them produced more than 33% yield of the desired N-benzyl-N 0 -tboc-bispidine 11. We found the Huang-Minlon variation of the Wolff-Kishner reduction suitable to produce 11 in yields as high as 73%, if the reaction temperature would not exceed 140°C. 24, 25, 49 The desired intermediate N-benzyl-N 0 -tboc-bispidine 11 was obtained after purification by flash chromatography.
N-benzylbispidine 12 could be obtained by cleaving the N-tboc protection group under acidic conditions, for example, with hydrochloric acid in 1,4-dioxane. Exceeding 140°C in the above mentioned Wolff-Kishner reaction (Huang-Minlon variation) also lead to N-benzylbispidine 12 but side product formation hampered the purification process. N-benzylbispidine 12 could also be used as an intermediate to further substitute the secondary amine of 12, but the purification of the N-benzyl protected intermediates was often more difficult and cumbersome than the purification of the N-tboc protected intermediates. Furthermore, the final Nbenzyl deprotection often produced low yields depending on the nature of the substituent. Therefore, the N-benzyl protection group was cleaved first leading to N-tboc protected intermediates, which could easily be purified and cleaved from the N-tboc group in a final step (Scheme 1).
The N-benzyl protecting group was cleaved from N-benzyl-N 0 -tboc-bispidine 11 using palladium on activated charcoal (Pd/C) 5% as a catalyst under a hydrogen atmosphere. The resulting N-tboc-bispidine 13 was obtained in quantitative yields and no further purification was necessary besides filtering off the catalyst.
N-tboc-Bispidine 13 was used as a starting material to introduce a wide variety of moieties to the bispidine backbone (Scheme 1). Different synthetic approaches were used to synthesize N-tboc protected 3,7-diazabicyclo[3.3.1]nonane carboxamides, sulfonamides or urea compounds (Scheme 1). [50] [51] [52] [53] [54] The N-tboc protected intermediates Boc-8, Boc-15-63, and Boc-67-69 were isolated and purified, but not analyzed and described in detail. Boc-8 and Boc-15-33 intermediates were synthesized by aminolysis of N-tboc-bispidine and various carboxylic acid chlorides. Due to the simplicity of this reaction and the fact that many carboxylic acids are commercially available in form of their acid chlorides, we preferred this method. Purification was accomplished by flash chromatography. Aminolysis was also used to synthesize Ntboc protected sulfonamides Boc-34-40 and the urea compounds Boc-41-42. 1,1 0 -Carbonyldiimidazole (CDI) as coupling reagents was used when certain carboxylic acid chlorides were not available. For the CDI method, N-tboc-bispidine 13 was allowed to react with CDI, and N-carbonylimidazolyl-N 0 -tboc-bispidine 14 was isolated after chromatographic purification. Then, 14 was activated with an excess of MeI, and Et 3 N and the carboxylic acid were added subsequently. Flash chromatography provided the N-tboc protected bispidinecarboxamides Boc-44-55. DCC was used as an alternative method, when CDI did not produce satisfying yields. Using the DCC method, N-tboc-bispidine 13, the carboxylic acid, DCC and N,N-dimethylaminopyridine (DMAP) were dissolved in CH 2 Cl 2 at 0°C and allowed to react at rt for 12 h. After filtering off the dicyclohexyl urea by-product, the N-tboc protected 3,7-diazabicyclo[3.3.1]nonane carboxamides were purified by flash chromatography. Occasionally, a second filtration or a second chromatographic step was required to eliminate residual dicyclohexyl urea by-product.
For the synthesis of Boc-67-69, the three aliphatic, cyclic amines (pyrrolidine, morpholine and 4-benzylpiperidine) were allowed to react with CDI. The carbonylimidazole adducts 64-66 were obtained after extraction, and activated with methyliodide, subsequently. The activated adducts were coupled with N-tbocbispidine 13, and the N-tboc protected bispidine urea derivatives Boc-67-69 were purified by flash chromatography.
A small homologous series 69-71 (methyl, ethyl, propyl) of acetylbispidine 8 was prepared to investigate the influence of the secondary versus a tertiary amine group at the 3,7-diazabicyclo[3.3.1]nonane scaffold on the interaction with a4b2 ⁄ nAChRs. The compounds were obtained by alkylating acetylbispidine 8 with alkyl iodides in the presence of K 2 CO 3 in DMF. The final products could be obtained after flash chromatography. N-Methyl-acetylbispdine 70 has been synthesized before but was neither tested for nAChR affinity nor have analytical data been published. 55 The cleavage of the N-tboc protecting group from Boc-8, Boc-15-63, and Boc-69-71 was accomplished by using acidic conditions at room temperature, either hydrogen chloride in 1,4-dioxane or anhydrous ZnBr 2 in CH 2 Cl 2 . 56 Both methods resulted in the desired bispidine derivatives 8, 15-63, and 67-69 after alkaline workup. Most compounds were transferred into their corresponding salt forms, either fumaric or hydrochloric acid salts for in vitro testing. This is indicated as 'F' or 'H' for the compounds in the Section 4 and the compounds are also analyzed in their salt forms. The salt formation step was advantageous for further purifying our final compounds from residual N-tboc-protected 3,7-diazabicyclo[ 3.3.1]nonane derivatives or other by-products. 40, 48, 62, 63 , and 70-72 were used as free bases.
Biological activity and structure-activity relationship (SAR)
The affinities of the 3,7-diazabicyclo[3.3.1]nonane derivatives 8, 12-13, 15-63, and 67-72 were determined in radioligand binding studies as previously described. 38, 39, 57 In contrast, N-tboc-bispidine 13 has high affinity for the a4b2 ⁄ subtype in the low nanomolar range (K i = 45 nM) whereas affinity for the a3b4 ⁄ subtype was in the low micromolar range (K i = 1.3 lM).
In general, all active compounds except for the intermediate N-
benzyl-bispidine 12 showed higher affinity for the a4b2 ⁄ nAChR subtype than for the other subtypes tested.
As we reported before, acetylbispidine 8 can be considered as a simplified cytisine 3 analog missing the pyridone moiety, but still displaying the same pharmacophoric components as 3 (Fig. 1) , the protonable secondary nitrogen and the carbonyl functionality which serves as a HBA system. [24] [25] [26] Compound 8 can also be considered as a more rigid and stable analog of ACh 1. In contrast to the rigid cytisine 3 (Table 1) , acetylbispidine 8 showed reduced affinity for all subtypes measured ( It is known that a tertiary amine motif in cytisine, displayed in the naturally occurring compound caulophylline, reduces the a4b2 ⁄ nAChR affinity. 37 Similar observations have also been made for tetrahydrocytisine 6 and its N-methyl analog 7. To study the more flexible compounds bearing the same diazabicyclic scaffold attached to the same HBA linker, we evaluated three N-alkyl analogs of acetylbispidine (cpds 70-72). There is a dramatic decrease of a4b2
⁄ affinity from N-methyl (K i = 200 nM) to N-propyl (K i >5000 nM; Table 3 ). Only the methyl group was tolerated but produced a compound with a 35-fold lower affinity for the a4b2 ⁄ subtype.
Simple aryl substituents: With the introduction of an aromatic moiety at the 3,7-diazabicyclo[3.3.1]nonane carboxamide template (19) , a reduction of affinity was observed compared to acetylbispidine 8, but 19 displayed higher affinity comparing with its saturated cyclohexyl derivative 18. Benzoylbispidine 19 exhibited affinity for the a4b2 ⁄ nAChR subtype in the nanomolar range (K i = 453.6 nM) and did not show any affinity for the other receptor subtypes tested. Table 2 Affinities (K i values ± SEM) and calculated physicochemical parameters (log P, TPSA, log BB) of bispidine, the bispidine intermediates 12 and 13 and of the bispidine carboxamide derivatives 8, 15-33, and 43-63 Additional substitution at the aromatic part provided important insight into structural requirements for a4b2
⁄ nAChR ligands. The steric input caused by substituents at the ortho position resulted in a complete loss of activity. Substitution at the ortho position (compounds 44, 20, and 21) is likely to force the aromatic ring to an out-of-plane arrangement which seems to be not tolerated by the nAChRs evaluated. Compounds with a substitution at the meta position of the phenyl ring 45 (3-fluoro) and 46 (3-trifluoromethyl) showed affinity in the nanomolar range for the a4b2 ⁄ subtype (K i = 386.4 nM and K i = 147.1 nM, respectively), but compounds 22 (3-chloro) and 23 (3-nitro) were inactive at this receptor subtype. This seems to indicate that small electron withdrawing groups (fluoro 45, trifluoromethyl 46) are still tolerated in the meta position, whereas bulkier electron withdrawing groups (chloro 22, nitro 23) are not.
Compounds with substitution at the para position of the phenyl ring 24-28, 47-49, and 56 exhibited higher affinities for a4b2 ⁄ nAChR in most cases compared with the meta-substituted ligands except for the bulky 4-tert-butyl group (25, K i values >10,000 nM), or if an additional ortho substituent was present Values are generated from 2 to 10 independent experiments; ⁄ = radioligand binding was increased; n. d. = not determined. a n = 2. b C log P values have been calculated using the ACD/Labs Algorithm. c log P calculated with the ACD/Labs Algorithm was used to calculate log BB.
Table 3
Affinities (K i values ± SEM) and calculated physicochemical parameters (log P, TPSA, log BB) of the bispidine sulfonamides 34-40, bispidine urea derivatives 41-42, 67-69, and alkylated acetylbispidine derivatives 70-72 Values are generated from 2 to 10 independent experiments; a n = 2; n. d. = not determined. b C log P values have been calculated using the ACD/Labs Algorithm. c log P calculated with the ACD/Labs Algorithm was used to calculate log BB. (2,4- 22, 23, 28 The N-methyl-pyrrol-2-yl derivative (59) showed less affinity for the a4b2
⁄ subtype compared to 30 and 31, which could be due to its N-methyl substituent mimicking an ortho-substituent. In contrast to 44 (2-methylphenyl), which is lacking any affinity, 59 displayed a K i value of 661.6 nM for this subtype. Bispidine amide derivatives substituted with small five-membered aromatic ring systems (30 and 31) , including hetero atoms with hydrogen bond acceptor properties, are likely to enhance the affinity for a4b2 ⁄ nAChR. Fused heteroaryl substituents: The influence of fused aryl systems (naphthoyl derivatives 32 and 33) was already mentioned above, but the introduction of an additional nitrogen atom at various positions created some additional important aspects. If the nitrogen is in close proximity to the carbonyl function (e.g., 2-quinolinyl compound 52, 2-indole compound 60, or 3-indole compound 61), the affinity drops enormously or even disappears, and this is regardless of the HB nature of this nitrogen. Interestingly, the naphthoyl derivative 33, showed affinity in the higher nanomolar range for a4b2 ⁄ (K i = 447.2 nM), whereas the nitrogen in 52 causes a dramatic drop (K i >1000 nM). In contrast, the quinolin-6-yl analog 54 displayed an increase in affinity (K i = 81.3 nM) compared to its non nitrogen containing naphthoyl derivative 33. The affinity of the naphthoyl derivative 32, which showed a K i value of >10,000 nM for a4b2 ⁄ could be improved by the introduction of a nitrogen observed in the quinolin-4-yl analog 53 displaying a K i value of 162.1 nM for a4b2 ⁄ . In summary, fused N-heteroaryl systems with nitrogen atoms in close proximity to the HBA/carbonyl group showed a reduced affinity for the a4b2 ⁄ subtype compared to compounds bearing the nitrogen atom in a longer distance to this group.
HBA linkers: To investigate the influence of the carboxamide linker as the HBA group, we replaced it by a sulfonamide or urea group. As shown in Table 3 Table 2 ) exhibited lower or no affinity for the a4b2 ⁄ subtype. Thus, the replacement of the carboxamide linker by a sulfonamide group erases or decreases the affinity of the compounds for the a4b2 ⁄ subtype. The sulfonamide linker has a weaker HB basicity than the carboxamide, but this difference is too small to explain the strong influence on affinity. The impact of change in linker geometry and therefore the orientation of the HBA system in space seem to be of much higher importance.
Since both an acyclic amide and acyclic urea have about the same HB basicity, compounds with urea linker were investigated for affinity. The N,N-dimethyl urea compound 41 showed an affinity in the nanomolar range (K i = 499.3 nM) for the a4b2 ⁄ subtype, but the homologous N,N-diethyl urea analog 42 lost its affinity. Interestingly, compound 41 displayed a 10-fold lower affinity for the a4b2 ⁄ nAChR than the corresponding carboxamide analog 17. From the three cyclic urea compounds 67-69 only the morpholino compound 68 had affinity for the a4b2 ⁄ subtype, however, only in the micromolar range (K i = 3.8 micromolar). The carboxamide analog 43 exhibited high affinity in the low nanomolar range (K i = 10.8 nM), whereas its urea analog 67 was not active. Taken together this emphasises that the urea group cannot replace the carboxamide linker at the bispidine backbone and that bulkier alkyl groups are not tolerated by the receptor. Similar observations have been obtained in the affinity evaluation of a7 ⁄ ligands bearing the 1,4-diazabicyclo[3.2.2]-nonane scaffold which was directly linked via a sulfonamide or urea motif to a spectrum of phenyl substituents. 58 The affinity dropped enormously in this case in contrast to a carbamate functionality used. 58 Selected compounds showing affinity for a4b2
⁄ in the lower nanomolar range were evaluated electrophysiologically in an initial characterization for their functionality using human and mouse (for muscle) nAChRs expressed in Xenopus oocytes (Fig. 3) . 59 ⁄ and a7 of 43 changed to having essentially no effect at a3b4 ⁄ and apparent antagonistic activity at a7 and muscle types. In general, small alkyl substituents showed the tendency towards agonism at a4b2 ⁄ , a3b4
⁄ (strongest for compound 16), and a7, whereas aromatic substituents displayed partial agonism/antagonism (e.g. compound 47). Several research groups have used the bispidine scaffold for the development of nAChR ligands like mentioned before, but most of them were focused on the development of a4b2 agonists and the chemical space used was limited. Our first part of an extensive SAR investigation around the bispidine scaffold showed that a carboxamide HBA system was preferred over other HBA systems investigated here. Parasubstitution in the phenyl group series was best tolerated and could serve as a starting point for further evaluation of the chemical space for a4b2 ⁄ ligands. Compounds 47 and 55 gave first hints that the introduction of a spacer motif has an important impact on functionality leading to ligands with a possible antagonistic profile speculating about an additional binding site accessible through a spacer motif. Therefore, a more detailed SAR examination on spacer motifs will be presented in another study (''part 2''). Both studies were the foundation for the development of in vivo active compounds recently published. 62 
Physicochemical properties and druglikeness
ACD/ADME Suite 5.0 (ACD/Labs) software has been used to calculate physicochemical properties and druglikeness parameters (e.g., ClogP, TPSA, and log BB; Tables 1-3 ). The compounds do not violate the Ro5. 63 Some physicochemical properties associated with drug-likeness parameters for CNS drugs are ideally between 250 and 350 for Mr, C log P between 1-3, PSA <75, and more parameters important for CNS compounds have been calculated (Table 4; Supplementary data) for compounds showing nanomolar affinity for a4b2
⁄ (K i <1000 nM). 64 Most active compounds showed 'good' or 'acceptable' values for most parameters calculated. There were no correlations between affinity and C log P or TPSA values. The log BB values can also be used to estimate the likelihood for blood-brain barrier (BBB) penetration. Values below À0.5 would reflect very poor or no BBB penetration and >0.7 very high penetrants. The cyano group is producing a borderline TPSA value, and especially the nitro group shows the least ideal values for TPSA and log BB. In addition, the nitro group is also a toxophoric group and along with bromoaryl substituents which could also produce toxic metabolites, both are here only used to get a fast SAR insight regarding lipophilic input, steric aspects, and additional pharmacophoric points.
Conclusions
We prepared a simple series of 3,7-diazabicyclo[3.3.1]nonane based compound series with three different HBA linkers and evaluated their affinities and initial functionality for different nAChR subtypes. The scaffold 3,7-diazabicyclo[3.3.1]nonane displaying the essential pharmacophoric element for cation-p/HB interaction has an affinity for a4b2 ⁄ in the higher nanomolar range (K i = 600 -nM) and weak a7 agonism. Intermediates in the synthetic pathway of this series like N-tboc-bispidine 13 and N-benzyl-bispidine 12 are active at nAChRs and display different subtype preferences. Structure-activity relationship studies revealed that the carboxamide linker was preferred over a sulfonamide or urea motif. Active carboxamide derivatives showed selectivity for the a4b2 ⁄ nAChR except for small hydrocarbon substituents which exhibit high affinity for the a4b2 ⁄ nAChR subtype but comparably low selectivity over a3b4 ⁄ and a7
⁄ subtypes. These compounds displayed also more agonistic profiles for the neuronal subtypes. Para-substituted benzoylbispidines with small electron withdrawing groups were well tolerated by the a4b2 ⁄ nAChR displaying nanomolar affinities. The impact of heteroaryl substituents (fivemembered, six-membered, fused) on a4b2 ⁄ affinity were dependent on size and the position of the heteroatom.
Further SAR studies will focus on the influence of an additional spacer motif between the HBA system and the attached substituent moiety.
In summary, the 3,7-diazabicyclo[3.3.1]nonane scaffold can serve as an important starting point for the development of nAChR compounds with diverse and desired affinity and functionality pattern.
Experimental section
All reagents and solvents were obtained from various suppliers (ABCR, Acros, Aldrich, Alfa Aesar, Fluka, Merck or Sigma) and used without further purification unless otherwise noted. Dichloromethane was freshly distilled from calcium hydride. Methanol was treated with sodium, distilled afterwards and stored under nitrogen. Sodium wires were used to dry diethyl ether, petroleum ether, tetrahydrofuran, and toluene. Water was taken from a water purification system PureLab Plus UV (ELGA Labwater) or Direct-Q™ 5 (Millipore). Amines were purified prior to use with a Kugelrohr distillation apparatus (Büchi). Reactions were monitored by thin-layer chromatography (TLC) using aluminum sheets coated with silica gel 60 F 254 (Merck). Compounds were visualized using UV light (254 or 365 nm) and using a KMnO 4 solution (1% in water). Column chromatography was carried out on silica gel (0.035-0.060 nm) using different mixtures of CH 2 Cl 2 with MeOH (40:1, 20:1 or 9:1) or of PE with EtOAc (4:1 or 3:1) as mobile phases. 1 H NMR spectra (400 or 500 MHz) and 13 C NMR spectra (100 or 125 MHz) were recorded on an Avance 400 or on an Avance 500 NMR spectrometer (Bruker). All NMR spectra were recorded at rt. Chemical shifts (d) are given in parts per million (ppm) relative to the remaining protons of the deuterated solvents used as internal standard. Coupling constants J are given in Hertz (Hz) and spin multiplicities are given as s (singlet), d (doublet), dd (doublet of doublets), t (triplet), q (quartet), m (multiplet) and br (broad). Mass spectra were recorded on an API 2000 mass spectrometer with an electron spray ionization source (Applied Biosystems) coupled to Compounds in their salt form are named with 'F' or 'H' along with their number, and they are also analyzed in their salt forms.
General procedure A: synthesis of N-tboc protected bispidinecarboxamides, bispidinesulfonamides, or bispidine urea derivatives
The appropriate carboxyl chloride, sulfonyl chloride, or carbamoyl chloride (1 mmol), either neat or dissolved in dry toluene (1-2 mL), was added dropwise to a stirred solution of N-tboc-bispidine 13 (230 mg, 1 mmol) and Et 3 N (101 mg, 1 mmol) in dry toluene (5 mL) at rt. The volatiles were removed under reduced pressure after 2 h and the residue was purified by flash chromatography (silica gel, mixtures of CH 2 Cl 2 and MeOH-40:1, 20:1 or 9:1).
General procedure B: synthesis of N-tboc protected bispidinecarboxamides
Methyl iodide (570 mg, 4 mmol) was added to a stirred solution of 14 (320 mg, 1 mmol) dissolved in dry MeCN (2 mL) and dry THF (2 mL) at rt. The volatiles were removed under reduced pressure after 24 h, the residue was dissolved in dry MeCN (4 mL), and Et 3 N (101 mg, 1 mmol) and the appropriate carboxylic acid (1 mmol) were added. The solution was allowed to stir at rt for 12-120 h before the volatiles were removed under reduced pressure. The residue was purified by flash chromatography (silica gel, mixtures of CH 2 Cl 2 and MeOH-40:1, 20:1 or 9:1).
General procedure C: synthesis of N-tboc protected bispidinecarboxamides
The appropriate carboxylic acid (1 mmol) and N-tboc-bispidine 13 (248 mg, 1.1 mmol) were dissolved in dry CH 2 Cl 2 (5 mL) and cooled to 0°C. DMAP (6.1 mg, 0.05 mmol) and DCC (206 mg, 1 mmol) were added and the mixture was allowed to warm up and stir at rt. The precipitate was filtered off after 12 h and washed with cold CH 2 Cl 2 (2 mL). The solvent of the filtrate was evaporated under reduced pressure and the residue was purified by flash chromatography (silica gel, mixtures of CH 2 Cl 2 and MeOH-40:1. 20:1 or 9:1).
General procedure D: cleavage of the N-tboc protecting group from N-tboc protected bispidine derivatives
HCl in 1,4-dioxane (4 M, 4-5 mL) was added to a stirred solution of the N-tboc protected bispidine derivative (0.2-1.0 mmol), dissolved in 4-5 mL of 1,4-dioxane, and the mixture was allowed to stir at rt for 2-12 h. The volatiles were removed under reduced pressure before the residue was dissolved in KOH solution (0.25 M, 20 mL) and extracted with CH 2 Cl 2 (3-5 Â 20 mL). The combined organic layers were washed with saturated NaHCO 3 solution (10 mL), water (10 mL), dried with MgSO 4 and filtered. The product was obtained after evaporating the solvent under reduced pressure.
General procedure E: cleavage of the N-tboc protecting group from N-tboc protected bispidine derivatives
The N-tboc protected bispidine derivative (0.2-1.0 mmol) was dissolved in dry CH 2 Cl 2 (5 mL), anhydrous ZnBr 2 (2-3 equiv) was added, and the mixture was allowed to stir at rt for 12-120 h. After the removal of the volatiles under reduced pressure the residue was dissolved in KOH solution (0.25 M, 20 mL) and extracted with CH 2 Cl 2 (5 Â 20 mL). The combined organic layers were washed with saturated NaHCO 3 solution (10 mL), water (10 mL), dried over MgSO 4 , and filtered. The product was obtained after evaporating the solvent under reduced pressure.
General procedure F: formation of fumaric acid salts of bispidine derivatives
The amine (0.2-1.0 mmol) was dissolved in a mixture of Et 2 O and MeOH (9:1, 2-5 mL). A saturated solution of fumaric acid in the same mixture of solvents was added dropwise to a stirred solution of the amine until no further precipitation was observed. The solution was kept at 4-8°C overnight before the precipitate was filtered off and washed with the same mixture of solvents (2 Â 5 mL) and dry Et 2 O (5 mL). The solid was dissolved in water (20-30 mL), and freeze-dried.
General procedure G: formation of fumaric acid salts of bispidine derivatives
The amine (0.2-1.0 mmol) was dissolved in isopropanol (3-5 mL), filtered, and heated to 70-80°C. The same molar amount of fumaric acid was dissolved in isopropanol (3 mL) and also heated to 70-80°C. The two solutions were combined and allowed to cool to rt. Dry Et 2 O (10 mL) were added and the mixture was kept at 4-8°C overnight. The solid was filtered off, washed with dry Et 2 O (3 Â 5 mL), dissolved in water (20-30 mL), and freezedried.
General procedure H: synthesis of alkyl substituted acetylbispidine derivatives
Acetylbispidine 8 (110 mg, 0.65 mmol) was dissolved in 4 mL of dry DMF and K 2 CO 3 (90.4 mg, 0.65 mmol) and the appropriate alkyl iodide (0.65 mmol) were added. The reaction was allowed to stir at rt for 12 h before the volatiles were removed under reduced pressure. The residue was dissolved in aqueous KOH solution (1 M, 5 mL) and extracted with CH 2 Cl 2 (3 Â 5 mL). The combined organic layers were dried with MgSO 4 , filtered, and the solvent was removed under reduced pressure. The residue was purified by flash chromatography on silica gel using a mixture of CH 2 Cl 2 and MeOH (20:1 or 9:1) as eluents. After evaporating the solvents the final products were obtained as clear oils.
3,7-Diazabicyclo[3.3.1]nonane dihydrochloric acid salt (bispidine dihydrochloric acid salt)
N-tboc-bispidine 13 (150 mg, 0.66 mmol) was dissolved in 1,4-dioxane (3 mL) and a HCl/1,4-dioxane mixture (4 M) was added. The volatiles were removed under reduced pressure after 6 h (stirring at rt). The N-tboc protected compound was obtained by using general procedure A with acetyl chloride (79 mg, 1 mmol). A mixture of CH 2 Cl 2 and MeOH (9:1) was used for the chromatographic purification. After removal of the solvents a white solid (268 mg, 98%) was obtained. The N-tboc protection group of this solid (250 mg, 0.93 mmol) was cleaved using general procedure E with anhydrous ZnBr 2 (420 mg, 1.86 mmol) for 48 h and an off white solid 8 (146 mg, 93%) was obtained after extraction. This solid 8 (48 mg, 0.29 mmol) was transferred to its fumaric acid salt 8F by using the general procedure G with fumaric acid (33 mg, 0.29 mmol). Compound 8F (66 mg, 69%) was obtained as a white solid in 63% yield over three steps; mp 152-156°C (dec). Compound 10 was obtained following the synthetic procedures published by Stead et al. 46 A solution of tert-butyl 4-oxopiperidine-1-carboxylate 9 (10.0 g, 50.2 mmol), acetic acid (2.9 mL, 50.9 mmol), and benzylamine (5.5 mL, 50.4 mmol) in methanol (40 mL) was added dropwise to a stirred suspension of paraformaldehyde (3.32 g, 110.6 mmol). The resulting mixture was heated under reflux for 1 h before another portion of paraformaldehyde (3.32 g, 110.6 mmol) was added. This mixture was heated at reflux for additional 5 h before the reaction was allowed to cool to rt and the solvent was evaporated under reduced pressure. A solution of 10 (18.9 g, 57.2 mmol), NaOH (10.0 g, 250 mmol), and hydrazine hydrate (80%, 10.0 mL, 160 mmol) in 150 mL of diethylene glycol was heated at 125°C under reflux conditions. After 2 h the reflux condenser was exchanged for a Dean-Stark apparatus and the mixture was heated at 140°C for additional 8 h. After cooling to rt 250 mL of water were added and the resulting mixture was extracted with toluene (4 Â 150 mL). The combined organic layers were washed with saturated NaHCO 3 solution (1 Â 30 mL), water (2 Â 30 mL), dried with MgSO 4 and filtered. The solvent was evaporated under reduced pressure and the residue was purified by flash chromatography (silica gel, PE:EtOAc 4:1) to afford 11 as a white solid (13.2 g, 73%); mp 66°C. 1 HCl dissolved in 1,4-dioxane (4 M, 6 mL) was added to a solution of 11 (192 mg, 0.61 mmol) in 1,4-dioxane (6 mL). The mixture was stirred at rt for 12 h before the volatiles were evaporated under reduced pressure. The residue was dissolved in aqueous KOH solution (1 M, 20 mL) and extracted with Et 2 O (3 Â 20 mL). The combined organic layers were dried with MgSO 4 , filtered, and the solvent was evaporated under reduced pressure. General procedure F afforded 12F as an off-white solid (139 mg, 0.42 mmol, 68% over two steps); mp 167-170°C (dec). 1 200 mg of Pd/C (5%) was added to a solution of 11 (1.5 g, 4.74 mmol) in MeOH (7 mL) and the mixture was allowed to react under an atmosphere of hydrogen (10 psi) at rt for 4 h. After the mixture was filtered and washed thoroughly with MeOH the solvent was evaporated under reduced pressure. The product was obtained as a clear oil (1.05 g, 4.64 mmol) in 98% yield. The free amine 13 was used for further syntheses. General procedure F was used to transfer this clear oil 13 (161 mg, 0.71 mmol) into a white solid, its fumaric acid salt 13F (200 mg, 82%); mp 170°C (dec). 1 The N-tboc protected compound was obtained by using the general procedure A with butyryl chloride (107 mg, 1 mmol). A mixture of CH 2 Cl 2 and MeOH (20:1) was used for the chromatographic purification. After removal of the solvents a white solid (292 mg, 97%) was obtained. The N-tboc protection group of this solid (200 mg, 0.67 mmol) was cleaved using the general procedure D for 12 h and a yellowish oil 16 (128 mg, 97%) was obtained after extraction. This oil 16 (45 mg, 0.23 mmol) was transferred to its fumaric acid salt 16F by using the general procedure G with fumaric acid (27 mg, 0.23 mmol). Compound 16F (46 mg, 73%) was obtained as a white solid in 59% yield over three steps; mp 159-161°C (dec). The N-tboc protected compound was obtained by using the general procedure A with isobutyryl chloride (107 mg, 1 mmol) The N-tboc protected compound was obtained by using the general procedure A with cyclohexanecarbonyl chloride (147 mg, 1 mmol). A mixture of CH 2 Cl 2 and MeOH (20:1) was used for the chromatographic purification. After removal of the solvents a white solid (332 mg, 97%) was obtained. The N-tboc protection group of this solid (220 mg, 0.65 mmol) was cleaved using the general procedure D for 18 h and a white solid 18 (153 mg, 99%) was obtained after extraction. This solid 18 (93 mg, 0.39 mmol) was transferred to its fumaric acid salt 18F by using the general procedure G with fumaric acid (46 mg, 0.39 mmol). Compound 18F (107 mg, 73%) was obtained as a white solid in 70% yield over three steps; mp 166-167°C (dec). The N-tboc protected compound was obtained by using the general procedure A with benzoyl chloride (141 mg, 1 mmol). A mixture of CH 2 Cl 2 and MeOH (20:1) was used for the chromatographic purification. After removal of the solvents a white solid (325 mg, 97%) was obtained. The N-tboc protection group of this solid (200 mg, 0.61 mmol) was cleaved using the general procedure D for 12 h and an off white solid 19 (138 mg, 99%) was obtained after extraction. This solid 19 (67 mg, 0.29 mmol) was transferred to its fumaric acid salt 19F by using the general procedure G with fumaric acid (34 The N-tboc protected compound was obtained by using the general procedure A with 2-chlorobenzoyl chloride (175 mg, 1 mmol). A mixture of CH 2 Cl 2 and MeOH (20:1) was used for the chromatographic purification. After removal of the solvents a white solid (323 mg, 87%) was obtained. The N-tboc protection group of this solid (250 mg, 0.69 mmol) was cleaved using the general procedure D for 12 h and a clear oil 20 (180 mg, 99%) was obtained after extraction. This solid 20 (96 mg, 0.36 mmol) was transferred to its fumaric acid salt 20F by using the general procedure G with fumaric acid (42 mg, 0.36 The N-tboc protected compound was obtained by using the general procedure A with 2-nitrobenzoyl chloride (186 mg, 1 mmol). A mixture of CH 2 Cl 2 and MeOH (20:1) was used for the chromatographic purification. After removal of the solvents a yellowish solid (371 mg, 97%) was obtained. The N-tboc protection group of this oil (290 mg, 0.77 mmol) was cleaved using the general procedure D for 18 h and a yellowish oil 21 (205 mg, 96%) was obtained after extraction. This oil 21 (103 mg, 0.37 mmol) was transferred to its fumaric acid salt 21F by using the general procedure G with fumaric acid (43 mg, 0.37 mmol). Compound 21F (95 mg, 65%) was obtained as a yellow solid in 61% yield over three steps; mp 184-185°C (dec). 1 The N-tboc protected compound was obtained by using the general procedure A with 3-chlorobenzoyl chloride (175 mg, 1 mmol). A mixture of CH 2 Cl 2 and MeOH (20:1) was used for the chromatographic purification. After removal of the solvents a clear oil (362 mg, 98%) was obtained. The N-tboc protection group of this oil (280 mg, 0.77 mmol) was cleaved using the general procedure D for 12 h and a white solid 22 (200 mg, 98%) was obtained after extraction. This solid 22 (132 mg, 0.50 mmol) was transferred to its fumaric acid salt 22F by using the general procedure G with fumaric acid (58 mg, 0.50 mmol). Compound 22F (126 mg, 58%) was obtained as a yellow solid in 56% yield over three steps; mp 163-165°C (dec). The N-tboc protected compound was obtained by using the general procedure A with 3-nitrobenzoyl chloride (186 mg, 1 mmol). A mixture of CH 2 Cl 2 and MeOH (20:1) was used for the chromatographic purification. After removal of the solvents a yellowish oil (369 mg, 97%) was obtained. The N-tboc protection group of this oil (290 mg, 0.77 mmol) was cleaved using the general procedure D for 18 h and a yellowish oil 23 (206 mg, 97%) was obtained after extraction. This oil 23 (87 mg, 0.32 mmol) was transferred to its fumaric acid salt 23F by using the general procedure G with fumaric acid (37 mg, 0.32 mmol). Compound 23F (101 mg, 79%) was obtained as a yellow solid in 74% yield over three steps; mp 166-169°C (dec). 1 The N-tboc protected compound was obtained by using the general procedure A with p-toluoyl chloride (155 mg, 1 mmol). A mixture of CH 2 Cl 2 and MeOH (20:1) was used for the chromatographic purification. After removal of the solvents a clear oil (322 mg, 92%) was obtained. The N-tboc protection group of this oil (200 mg, 0.58 mmol) was cleaved using the general procedure D for 12 h and an off white solid 24 (130 mg, 92%) was obtained after extraction. This solid 24 (49 mg, 0.20 mmol) was transferred to its fumaric acid salt 24F by using the general procedure G with fumaric acid (23 mg, 0.20 mmol). Compound 24F (49 mg, 56%) was obtained as a white solid in 47% yield over three steps; mp 166-167°C (dec). 
(1R,5S)-3,7-Diazabicyclo[3.3.1]nonan-3-yl(4-tertbutylphenyl)methanone fumaric acid salt (25F)
The N-tboc protected compound was obtained by using the general procedure A with 4-tert-butylbenzoyl chloride (197 mg, 1 mmol). A mixture of CH 2 Cl 2 and MeOH (20:1) was used for the chromatographic purification. After removal of the solvents a white solid (384 mg, 98%) was obtained. The N-tboc protection group of this solid (340 mg, 0.88 mmol) was cleaved using the general procedure D for 12 h and a white solid 25 (242 mg, 96%) was obtained after extraction. This solid 25 (113 mg, 0.39 mmol) was transferred to its fumaric acid salt 25F by using the general procedure G with fumaric acid (46 mg, 0.39 mmol). Compound 25F (100 mg, 60%) was obtained as a white solid in 56% yield over three steps; mp 151-153°C (dec). 1 The N-tboc protected compound was obtained by using the general procedure A with 4-fluorobenzoyl chloride (159 mg, 1 mmol). A mixture of CH 2 Cl 2 and MeOH (20:1) was used for the chromatographic purification. After removal of the solvents a clear oil (347 mg, 98%) was obtained. The N-tboc protection group of this oil (260 mg, 0.75 mmol) was cleaved using the general procedure D for 12 h and a clear oil 26 (178 mg, 96%) was obtained after extraction. This oil 26 (87 mg, 0.35 mmol) was transferred to its fumaric acid salt 26F by using the general procedure G with fumaric acid (41 mg, 0.35 mmol). Compound 26F (126 mg, 95%) was obtained as a white solid in 89% yield over three steps; mp 157-158°C (dec). 1 
(1R,5S)-3,7-Diazabicyclo[3.3.1]nonan-3-yl(4-chlorophenyl)methanone fumaric acid salt (27F)
The N-tboc protected compound was obtained by using the general procedure A with 4-chlorobenzoyl chloride (175 mg, 1 mmol). A mixture of CH 2 Cl 2 and MeOH (20:1) was used for the chromatographic purification. After removal of the solvents a clear oil (355 mg, 96%) was obtained. The N-tboc protection group of this oil (300 mg, 0.82 mmol) was cleaved using the general procedure D for 12 h and a clear oil 27 (211 mg, 97%) was obtained after extraction. This oil 27 (83 mg, 0.31 mmol) was transferred to its fumaric acid salt 27F by using the general procedure G with fumaric acid (36 mg, 0.31 mmol). Compound 27F (78 mg, 63%) was obtained as a yellow solid in 59% yield over three steps; mp 150-154°C (dec). 1 
(1R,5S)-3,7-Diazabicyclo[3.3.1]nonan-3-yl(4-bromophenyl)methanone fumaric acid salt (28F)
The N-tboc protected compound was obtained by using the general procedure A with 4-bromobenzoyl chloride (219 mg, 1 mmol). A mixture of CH 2 Cl 2 and MeOH (20:1) was used for the chromatographic purification. After removal of the solvents a white solid (406 mg, 99%) was obtained. The N-tboc protection group of this solid (320 mg, 0.78 mmol) was cleaved using the general procedure D for 18 h and a clear oil 28 (237 mg, 98%) was obtained after extraction. This oil 28 (134 mg, 0.43 mmol) was transferred to its fumaric acid salt 28F by using the general procedure G with fumaric acid (50 The N-tboc protected compound was obtained by using the general procedure A with 2,4-dimethoxybenzoyl chloride (201 mg, 1 mmol). A mixture of CH 2 Cl 2 and MeOH (20:1) was used for the chromatographic purification. After removal of the solvents a white solid (325 mg, 82%) was obtained. The N-tboc protection group of this solid (320 mg, 0.82 mmol) was cleaved using the general procedure E with anhydrous ZnBr 2 (369 mg, 1.6 mmol) for 12 h and a yellowish oil 29 (231 mg, 97%) was obtained after extraction. This oil 29 (96 mg, 0.33 mmol) was transferred to its fumaric acid salt 29F by using the general procedure G with fumaric acid (38 mg, 0.33 mmol). Compound 29F (106 mg, 78%) was obtained as an off white solid in 62% yield over three steps; mp 175°C (dec). 1 
(1R,5S)-3,7-Diazabicyclo[3.3.1]nonan-3-yl(furan-2-yl)methanone fumaric acid salt (30F)
The N-tboc protected compound was obtained by using the general procedure A with 2-furoyl chloride (131 mg, 1 mmol). A mixture of CH 2 Cl 2 and MeOH (20:1) was used for the chromatographic purification. After removal of the solvents a yellowish solid (267 mg, 82%) was obtained. The N-tboc protection group of this solid (240 mg, 0.75 mmol) was cleaved using the general procedure D for 12 h and a yellowish oil 30 (164 mg, 99%) was obtained after extraction. This oil 30 (79 mg, 0.36 mmol) was transferred to its fumaric acid salt 30F by using the general procedure G with fumaric acid (42 mg, 0.36 mmol). Compound 30F (48 mg, 38%) was obtained as an off white solid in 31% yield over three steps; mp 157-162°C (dec). 1 
(1R,5S)-3,7-Diazabicyclo[3.3.1]nonan-3-yl(thiophen-2-yl)methanone fumaric acid salt (31F)
The N-tboc protected compound was obtained by using the general procedure A with 2-thiophenecarbonyl chloride (147 mg, 1 mmol). A mixture of CH 2 Cl 2 and MeOH (20:1) was used for the chromatographic purification. After removal of the solvents a white solid (275 mg, 80%) was obtained. The N-tboc protection group of this solid (240 mg, 0.71 mmol) was cleaved using the general procedure D for 12 h and a yellowish solid 31 (150 mg, 89%) was obtained after extraction. This solid 31 (67 mg, 0.28 mmol) was transferred to its fumaric acid salt 31F by using the general procedure G with fumaric acid (33 mg, 0.28 mmol). Compound 31F (73 mg, 70%) was obtained as a white solid in 50% yield over three steps; mp 158-162°C (dec). 1 
(1R,5S)-3,7-Diazabicyclo[3.3.1]nonan-3-yl(naphthalene-1-yl)methanone fumaric acid salt (32F)
The N-tboc protected compound was obtained by using the general procedure A with 1-naphthoyl chloride (191 mg, 1 mmol). A mixture of CH 2 Cl 2 and MeOH (20:1) was used for the chromatographic purification. After removal of the solvents a white solid (353 mg, 91%) was obtained. The N-tboc protection group of this solid (240 mg, 0.63 mmol) was cleaved using the general procedure D for 12 h and a white solid 32 (172 mg, 97%) was obtained after extraction. This solid 32 (62 mg, 0.22 mmol) was transferred to the fumaric acid salt 32F by using the general procedure G with fumaric acid (26 mg, 0.22 mmol). Compound 32F (73 mg, 80%) was obtained as a white solid in 70% yield over three steps; mp 152-154°C (dec). 1 
(1R,5S)-3,7-Diazabicyclo[3.3.1]nonan-3-yl(naphthalene-2-yl)methanone fumaric acid salt (33F)
The N-tboc protected compound was obtained by using the general procedure A with 2-naphtoyl chloride (191 mg, 1 mmol). A mixture of CH 2 Cl 2 and MeOH (20:1) was used for the chromatographic purification. After removal of the solvents a white solid (342 mg, 88%) was obtained. The N-tboc protection group of this solid (250 mg, 0.66 mmol) was cleaved using the general procedure D for 12 h and a white solid 33 (181 mg, 98%) was obtained after extraction. This solid 33 (103 mg, 0.37 mmol) was transferred to the fumaric acid salt 33F by using the general procedure G with fumaric acid (43 mg 
(1R,5S)-3-(Methylsulfonyl)-3,7-diazabicyclo[3.3.1]nonane fumaric acid salt (34F)
The N-tboc protected compound was obtained by using the general procedure A with methylsulfonyl chloride (115 mg, 1 mmol) . A mixture of CH 2 Cl 2 and MeOH (20:1) was used for the chromatographic purification. After removal of the solvents a white solid (280 mg, 91%) was obtained. The N-tboc protection group of this solid (230 mg, 0.76 mmol) was cleaved using the general procedure D for 12 h and an white solid 34 (146 mg, 95%) was obtained after extraction. This solid 34 (110 mg, 0.54 mmol) was transferred to its fumaric acid salt 34F by using the general procedure G with fumaric acid (63 mg 
(1R,5S)-3-(Phenylsulfonyl)-3,7-diazabicyclo[3.3.1]nonane (35)
The N-tboc protected compound was obtained by using the general procedure A with benzenesulfonyl chloride (177 mg, 1 mmol). A mixture of CH 2 Cl 2 and MeOH (20:1) was used for the chromatographic purification. After removal of the solvents a white solid (324 mg, 87%) was obtained. The N-tboc protection group of this solid (90 mg, 0.25 mmol) was cleaved using the general procedure D for 4 h and compound 35 was obtained as an off white solid (63 mg, 96%) after extraction, in 84% yield over two steps; mp 101°C. 1 
3-((1R,5S)-3,7-Diazabicyclo[3.3.1]nonan-3-ylsulfonyl)benzonitrile (36)
The N-tboc protected compound was obtained by using the general procedure A with m-cyanophenylsulfonyl chloride (202 mg, 1 mmol). A mixture of CH 2 Cl 2 and MeOH (9:1) was used for the chromatographic purification. After removal of the solvents a white solid (385 mg, 98%) was obtained. The N-tboc protection group of this solid (200 mg, 0.51 mmol) was cleaved using the general procedure E with anhydrous ZnBr 2 (230 mg, 1.0 mmol) for 48 h and compound 36 was obtained as an off white solid (138 mg, 93%) after extraction, in 91% yield over two steps; mp 146°C. 1 
(1R,5S)-3-Tosyl-3,7-diazabicyclo[3.3.1]nonane (37)
The N-tboc protected compound was obtained by using the general procedure A with p-toluenesulfonyl chloride (190 mg, 1 mmol). A mixture of CH 2 Cl 2 and MeOH (9:1) was used for the chromatographic purification. After removal of the solvents a white solid (377 mg, 97%) was obtained. The N-tboc protection group of this solid (200 mg, 0.53 mmol) was cleaved using the general procedure E with anhydrous ZnBr 2 (237 mg, 1.1 mmol) for 48 h and compound 37 was obtained as an off white solid (145 mg, 98%) after extraction, in 95% yield over two steps; mp 111°C. 1 
4-((1R,5S)-3,7-Diazabicyclo[3.3.1]nonan-3-ylsulfonyl)benzonitrile (38)
The N-tboc protected compound was obtained by using the general procedure A with p-cyanophenylsulfonyl chloride (202 mg, 1 mmol). A mixture of CH 2 Cl 2 and MeOH (9:1) was used for the chromatographic purification. After removal of the solvents a white solid (295 mg, 75%) was obtained. The N-tboc protection group of this solid (200 mg, 0.51 mmol) was cleaved using the general procedure E with anhydrous ZnBr 2 (230 mg, 1.0 mmol) for 48 h and compound 38 was obtained as an off white solid (105 mg, 71%) after extraction, in 53% yield over two steps; mp 169°C. 
(1R,5S)-3-(4-Bromophenylsulfonyl)-3,7-diazabicyclo[3.3.1]nonane hydrochloric acid salt (39H)
The N-tboc protected compound was obtained by using the general procedure A with p-bromophenylsulfonyl chloride (255.5 mg, 1 mmol). A mixture of CH 2 Cl 2 and MeOH (20:1) was used for the chromatographic purification. After removal of the solvents a white solid (407 mg, 91%) was obtained. This solid (264 mg, 0.59 mmol) was dissolved in a mixture of CH 2 Cl 2 (2 mL) and 1,4-dioxane (2 mL), HCl in 1,4-dioxane (4 M, 2 mL) was added for the cleavage of the N-tboc protection group, and the reaction mixture was allowed to stir at rt for 2 h. Then dry Et 2 O (2 mL) was added, the precipitate was filtered off, and washed with dry Et 2 O (3 Â 2 mL). Compound 39H (224 mg, 99%) was obtained as a white solid in 90% yield over two steps; mp 266-269°C (dec). 1 
(1R,5S)-3-(4-Nitrophenylsulfonyl)-3,7-diazabicyclo[3.3.1]nonane (40)
The N-tboc protected compound was obtained by using the general procedure A with p-nitrophenylsulfonyl chloride (222 mg, 1 mmol). A mixture of CH 2 Cl 2 and MeOH (40:1) was used for the chromatographic purification. After removal of the solvents a yellowish solid (272 mg, 65%) was obtained. The N-tboc protection group of this solid (253 mg, 0.61 mmol) was cleaved using the general procedure E with anhydrous ZnBr 2 (277 mg, 1.23 mmol) for 12 h and compound 40 was obtained as a yellowish solid (177 mg, 92%) after extraction, in 60% yield over two steps; mp 185°C (dec). The N-tboc protected compound was obtained by using the general procedure A with dimethylcarbamoyl chloride (108 mg, 1 mmol). A mixture of CH 2 Cl 2 and MeOH (20:1) was used for the chromatographic purification. After removal of the solvents a white solid (280 mg, 94%) was obtained. The N-tboc protection group of this solid (240 mg, 0.81 mmol) was cleaved using the general procedure D for 4 h and a white solid 41 (152 mg, 95%) was obtained after extraction. This solid 41 (140 mg, 0.71 mmol) was transferred to the fumaric acid salt 41F by using the general procedure G with fumaric acid (82 mg, 0.71 mmol). Compound 41F (180 mg, 81%) was obtained as a white solid in 72% yield over three steps; mp 144-148°C (dec). The N-tboc protected compound was obtained by using the general procedure A with diethylcarbamoyl chloride (135.6 mg, 1 mmol). A mixture of CH 2 Cl 2 and MeOH (20:1) was used for the chromatographic purification. After removal of the solvents a white solid (353 mg, 91%) was obtained. The N-tboc protection group of this solid (240 mg, 0.63 mmol) was cleaved using the general procedure D for 12 h and a white solid 42 (172 mg, 97%) was obtained after extraction. This solid 42 (62 mg, 0.22 mmol) was transferred to the fumaric acid salt 42F by using the general procedure G with fumaric acid (26 mg, 0.22 mmol). Compound 42F (73 mg, 80%) was obtained as a white solid in 70% yield over three steps; mp 111-115°C (dec). The N-tboc protected compound was obtained by using the general procedure B with cyclopentanecarboxylic acid (114 mg, 1 mmol) for 72 h. A mixture of CH 2 Cl 2 and MeOH (40:1) was used for the chromatographic purification. After removal of the solvents a white solid (228 mg, 71%) was obtained. The N-tboc protection group of this solid (198 mg, 0.61 mmol) was cleaved using the general procedure D for 12 h and a white solid 43 (134 mg, 98%) was obtained after extraction. This solid 43 (134 mg, 0.60 mmol) was transferred to its fumaric acid salt 43F by using the general procedure G with fumaric acid (70 mg, 0.60 mmol). Compound 43F (164 mg, 79%) was obtained as a white solid in 55% yield over three steps; mp 164-166°C (dec). The N-tboc protected compound was obtained by using the general procedure B with 2-methylbenzoic acid (136 mg, 1 mmol) for 48 h. A mixture of CH 2 Cl 2 and MeOH (20:1) was used for the chromatographic purification. After removal of the solvents a clear oil (186 mg, 54%) was obtained. The N-tboc protection group of this oil (165 mg, 0.48 mmol) was cleaved using the general procedure E with anhydrous ZnBr 2 (216 mg, 0.96 mmol) for 12 h and a white solid 44 (92 mg, 79%) was obtained after extraction. This solid 44 (77 mg, 0.32 mmol) was transferred to its fumaric acid salt 44F by using the general procedure G with fumaric acid (37 mg, 0.32 mmol). Compound 44F (61 mg, 52%) was obtained as a white solid in 22% yield over three steps; mp 155-157°C (dec). The N-tboc protected compound was obtained by using the general procedure B with 3-fluorobenzoic acid (140 mg, 1 mmol) for 24 h. A mixture of CH 2 Cl 2 and MeOH (20:1) was used for the chromatographic purification. After removal of the solvents a clear oil (230 mg, 66%) was obtained. The N-tboc protection group of this oil (210 mg, 0.60 mmol) was cleaved using the general procedure D for 12 h and a clear oil 45 (107 mg, 71%) was obtained after extraction. This oil 45 (96 mg, 0.39 mmol) was transferred to its fumaric acid salt 45F by using the general procedure G with fumaric acid (45 mg, 0.39 mmol). Compound 45F (84 mg, 58%) was obtained as a yellow solid in 27% yield over three steps; mp 157-158°C (dec). The N-tboc protected compound was obtained by using the general procedure B with 4-biphenylcarboxylic acid (198 mg, 1 mmol) for 12 h. A mixture of CH 2 Cl 2 and MeOH (40:1) was used for the chromatographic purification. After removal of the solvents a clear oil (293 mg, 72%) was obtained. The N-tboc protection group of this oil (250 mg, 0.61 mmol) was cleaved using the general procedure D for 12 h and a clear oil 47 (141 mg, 75%) was obtained after extraction. This oil 47 (60 mg, 0.20 mmol) was transferred to its fumaric acid salt 47F by using the general procedure G with fumaric acid (23 mg, 0.20 mmol). Compound 47F (54 mg, 63%) was obtained as a white solid in 34% yield over three steps; mp 148-150°C (dec). The N-tboc protected compound was obtained by using the general procedure B with 4-cyanobenzoic acid (147 mg, 1 mmol) for 12 h. A mixture of CH 2 Cl 2 and MeOH (9:1) was used for the chromatographic purification. After removal of the solvents a white solid (109 mg, 31%) was obtained. The N-tboc protection group of this solid (100 mg, 0.28 mmol) was cleaved using the general procedure D for 2 h and compound 48 was obtained as a white solid (69 mg, 96%) after extraction in 30% yield over two steps; mp 157°C (dec). 1 The N-tboc protected compound was obtained by using the general procedure B with 4-nitrobenzoic acid (167 mg, 1 mmol) for 12 h. A mixture of CH 2 Cl 2 and MeOH (40:1) was used for the chromatographic purification. After removal of the solvents a yellowish solid (184 mg, 49%) was obtained. The N-tboc protection group of this solid (170 mg, 0.45 mmol) was cleaved using the general procedure E with anhydrous ZnBr 2 (204 mg, 0.90 mmol) for 12 h and a yellowish solid 49 (76 mg, 61%) was obtained after extraction. This solid 49 (42 mg, 0.15 mmol) was transferred to its fumaric acid salt 49F by using the general procedure G with fumaric acid (18 mg, 0.15 mmol). Compound 49F (37 mg, 54%) was obtained as a yellow solid in 20% yield over three steps; mp 144-146°C (dec). The N-tboc protected compound was obtained by using the general procedure B with nicotinic acid (185 mg, 1 mmol) for 12 h. A mixture of CH 2 Cl 2 and MeOH (9:1) was used for the chromatographic purification. After removal of the solvents a clear oil (197 mg, 59%) was obtained. The N-tboc protection group of this oil (175 mg, 0.53 mmol) was cleaved using the general procedure E with anhydrous ZnBr 2 (358 mg, 1.6 mmol) for 72 h and a clear oil 50 (105 mg, 86%) was obtained after extraction. This oil 50 (48 mg, 0.21 mmol) was transferred to its fumaric acid salt 50F by using the general procedure G with fumaric acid (24 mg, 0.21 mmol). Compound 50F (47 mg, 63%) was obtained as a white solid in 32% yield over three steps; mp 144-148°C (dec). The N-tboc protected compound was obtained by using the general procedure B with 5-bromopyridine-3-carboxylic acid (303 mg, 1.5 mmol) for 12 h. A mixture of CH 2 Cl 2 and MeOH (40:1) was used for the chromatographic purification. After removal of the solvents a clear oil (166 mg, 41%) was obtained. The N-tboc protection group of this oil (210 mg, 0.51 mmol) was cleaved using the general procedure E with anhydrous ZnBr 2 (231 mg, 1.0 mmol) for 48 h and a yellowish oil 51 (142 mg, 89%) was obtained after extraction. This oil 51 (81 mg, 0.26 mmol) was transferred to its fumaric acid salt 51F by using the general procedure G with fumaric acid (30 mg, 0.26 mmol). Compound 51F (84 mg, 75%) was obtained as a white solid in 27% yield over three steps; mp 186-187°C (dec). 1 The N-tboc protected compound was obtained by using the general procedure B with 2-quinolinecarboxylic acid (173 mg, 1 mmol) for 72 h. A mixture of CH 2 Cl 2 and MeOH (20:1) was used for the chromatographic purification. After removal of the solvents a clear oil (210 mg, 55%) was obtained. The N-tboc protection group of this oil (180 mg, 0.47 mmol) was cleaved using the general procedure E with anhydrous ZnBr 2 (213 mg, 0.94 mmol) for 72 h and a yellowish oil 52 (130 mg, 98%) was obtained after extraction. This oil 52 (60 mg, 0.21 mmol) was transferred to its fumaric acid salt 52F by using the general procedure G with fumaric acid (25 mg, 0.21 mmol). Compound 52F (49 mg, 56%) was obtained as a white solid in 30% yield over three steps; mp 145-150°C (dec). The N-tboc protected compound was obtained by using the general procedure B with 4-quinolinecarboxylic acid (173 mg, 1 mmol) for 72 h. A mixture of CH 2 Cl 2 and MeOH (20:1) was used for the chromatographic purification. After removal of the solvents a clear oil (177 mg, 46%) was obtained. The N-tboc protection group of this oil (150 mg, 0.39 mmol) was cleaved using the general procedure E with anhydrous ZnBr 2 (177 mg, 0.79 mmol) for 72 h and a yellowish oil 53 (98 mg, 89%) was obtained after extraction. This oil 53 (45 mg, 0.16 mmol) was transferred to its fumaric acid salt 53F by using the general procedure G with fumaric acid (19 mg, 0.16 mmol The N-tboc protected compound was obtained by using the general procedure B with 6-quinolinecarboxylic acid (173 mg, 1 mmol) for 72 h. A mixture of CH 2 Cl 2 and MeOH (20:1) was used for the chromatographic purification. After removal of the solvents a clear oil (303 mg, 79%) was obtained. The N-tboc protection group of this oil (270 mg, 0.71 mmol) was cleaved using the general procedure E with anhydrous ZnBr 2 (319 mg, 1.4 mmol) for 72 h and a clear oil 54 (191 mg, 96%) was obtained after extraction. This oil 54 (45 mg, 0.16 mmol) was transferred to its fumaric acid salt 54F by using the general procedure G with fumaric acid (19 mg, 0.16 mmol). Compound 54F (27 mg, 40%) was obtained as a white solid in 30% yield over three steps; mp 162-165°C (dec). The N-tboc protected compound was obtained by using the general procedure C with cyclopentylacetic acid (128 mg, 1 mmol) for 12 h. A mixture of CH 2 Cl 2 and MeOH (20:1) was used for the chromatographic purification. After removal of the solvents a white solid (258 mg, 77%) was obtained. The N-tboc protection group of this solid (200 mg, 0.59 mmol) was cleaved using the general procedure D for 2 h and a white solid 55 (122 mg, 89%) was obtained after extraction. This solid 55 (122 mg, 0.52 mmol) was transferred to its fumaric acid salt 55F by using the general procedure G with fumaric acid (60 mg, 0.52 mmol). Compound 55F (152 mg, 84%) was obtained as a white solid in 58% yield over three steps; mp 162-164°C (dec). The N-tboc protected compound was obtained by using the general procedure C with 4-hydroxybenzoic acid (138 mg, 1 mmol) for 24 h. DMAP was not used for this reaction and the solvent was changed to THF. After the reaction was finished the precipitate was filtered off, washed with THF (3 Â 5 mL), and dried in a desiccator. A white solid (330 mg, 95%) was obtained. The N-tboc protection group of this solid (300 mg, 0.87 mmol) was cleaved using the general procedure D for 2 h and compound 56H was obtained as a white solid (210 mg, 86%) filtering and washing the precipitate with dry Et 2 O (3 Â 2 mL) as a white solid in 81% yield over two steps; mp >320°C (dec). The N-tboc protected compound was obtained by using the general procedure C with pyrazinecarboxylic acid (124 mg, 1 mmol) for 12 h. A mixture of CH 2 Cl 2 and MeOH (40:1) was used for the chromatographic purification. After removal of the solvents a white solid (285 mg, 86%) was obtained. The N-tboc protection group of this solid (231 mg, 0.69 mmol) was cleaved using the general procedure D with anhydrous ZnBr 2 (469 mg, 2.1 mmol) for 12 h and a yellowish oil 57 (160 mg, 99%) was obtained after extraction. This oil 57 (160 mg, 0.69 mmol) was transferred to its fumaric acid salt 57F by using the general procedure G with fumaric acid (80 mg, 0.69 mmol). Compound 57F (187 mg, 76%) was obtained as an orange solid in 65% yield over three steps; mp 154-156°C (dec). 1 The N-tboc protected compound was obtained by using the general procedure C with 6-chloropyridine-3-carboxylic acid (158 mg, 1 mmol) for 12 h. A mixture of CH 2 Cl 2 and MeOH (9:1) was used for the chromatographic purification. After removal of the solvents a white solid was obtained. The N-tboc protection group of this solid (340 mg, 0.92 mmol) was cleaved using the general procedure D 4 h and a clear oil 58 (244 mg, 98%) was obtained after extraction. This oil 58 (244 mg, 0.91 mmol) was transferred to its fumaric acid salt 58F by using the general procedure G with fumaric acid (105 mg, 0.91 mmol). Compound 58F (228 mg, 67%) was obtained as a white solid in 63% yield over three steps; mp 154-157°C (dec). The N-tboc protected compound was obtained by using the general procedure C with 1-methyl-2-pyrrolecarboxylic acid (125 mg, 1 mmol) for 12 h. A mixture of CH 2 Cl 2 and MeOH (40:1) was used for the chromatographic purification. After removal of the solvents an off white solid (325 mg, 98%) was obtained. The N-tboc protection group of this solid (297 mg, 0.89 mmol) was cleaved using the general procedure E with anhydrous ZnBr 2 (602 mg, 2.7 mmol) for 12 h and a yellowish oil 59 (201 mg, 97%) was obtained after extraction. This oil 59 (201 mg, 0.86 mmol) was transferred to its fumaric acid salt 59F by using the general procedure G with fumaric acid (100 mg, 0.86 mmol). Compound 59F (226 mg, 67%) was obtained as an off white solid in 64% yield over three steps; mp 136-137°C (dec). The N-tboc protected compound was obtained by using the general procedure C with indole-2-carboxylic acid (161 mg, 1 mmol) for 12 h. A mixture of CH 2 Cl 2 and MeOH (40:1) was used for the chromatographic purification. After removal of the solvents a white solid (353 mg, 96%) was obtained. The N-tboc protection group of this solid (340 mg, 0.92 mmol) was cleaved using the general procedure D for 4 h and a clear oil 60 (244 mg, 98%) was obtained after extraction. This oil 60 (244 mg, 0.91 mmol) was transferred to its fumaric acid salt 60F by using the general procedure G with fumaric acid (105 mg, 0.91 mmol). Compound 60F (228 mg, 67%) was obtained as a white solid in 63% yield over three steps; mp 198-200°C (dec). 1 The N-tboc protected compound was obtained by using the general procedure C with indole-3-carboxylic acid (161 mg, 1 mmol) for 12 h. A mixture of CH 2 Cl 2 and MeOH (20:1) was used for the chromatographic purification. After removal of the solvents a white solid (85 mg, 23%) was obtained. The N-tboc protection group of this solid (135 mg, 0.37 mmol) was cleaved using the general procedure D for 2 h and a yellowish oil 61 (97 mg, 99%) was obtained after extraction. This oil 61 (96 mg, 0.36 mmol) was transferred to its fumaric acid salt 61F by using the general procedure G with fumaric acid (41 mg, 0.36 mmol). Compound 61F (76 mg, 56%) was obtained as a white solid in 13% yield over three steps; mp 185-190°C (dec). 1 The N-tboc protected compound was obtained by using the general procedure C with indole-5-carboxylic acid (161 mg, 1 mmol) for 12 h. A mixture of CH 2 Cl 2 and MeOH (20:1) was used for the chromatographic purification. After removal of the solvents an off-white solid (364 mg, 98%) was obtained. The N-tboc protection group of this solid (200 mg, 0.54 mmol) was cleaved using the general procedure D for 4 h and compound 62 was obtained as a white solid (138 mg, 95%) after extraction, in 93% yield over two steps; mp 225-226°C. The N-tboc protected compound was obtained by using the general procedure C with 1H-indazole-6-carboxylic acid (162 mg, 1 mmol) for 12 h. A mixture of CH 2 Cl 2 and MeOH (20:1) was used for the chromatographic purification. After removal of the solvents a white solid (280 mg, 76%) was obtained. The N-tboc protection group of this solid (160 mg, 0.43 mmol) was cleaved using the general procedure D for 4 h and compound 63 was obtained as an offwhite solid (110 mg, 94%) after extraction, in 71% yield over two steps; mp 227-229°C. Compound 64 (182 mg, 1.1 mmol) was dissolved in 2 mL of MeCN and methyl iodide (625 mg, 4.4 mmol) was added. The solution was stirred at rt for 24 h before the volatiles were removed under reduced pressure. The residue was dissolved in 10 mL of CH 2 Cl 2 and Et 3 N (101 mg, 1 mmol) and N-tboc-bispidine 13 (226 mg, 1 mmol) were added. The solution was stirred at rt for another 24 h before it was washed twice with 5 mL of hydrochloric acid (1 M) and once with 5 mL of H 2 O. The organic layer was dried with MgSO 4 , filtered and the solvent is removed under reduced pressure. The residue was purified by flash chromatography using a mixture of CH 2 Cl 2 and MeOH (40:1) and after removal of the solvents a white solid (223 mg, 69%) was obtained. The N-tboc protection group of this solid (180 mg, 0.56 mmol) was cleaved using the general procedure D for 3 h and a white solid 67 (120 mg, 97%) was obtained after extraction. This solid 67 (105 mg, 0.47 mmol) was transferred to its fumaric acid salt 67F by using the general procedure F. Compound 67F (109 mg, 67%) was obtained as a white solid in 45% yield over three steps; mp 166-169°C (dec). 1 Compound 65 (182 mg, 1.1 mmol) was dissolved in 2 mL of MeCN and methyl iodide (625 mg, 4.4 mmol) was added. The solution was stirred at rt for 24 h before the volatiles were removed under reduced pressure. The residue was dissolved in 10 mL of CH 2 Cl 2 and Et 3 N (101 mg, 1 mmol) and N-tboc-bispidine 13 (226 mg, 1 mmol) were added. The solution was stirred at rt for another 24 h before it was washed twice with 5 mL of hydrochloric acid (1 M) and once with 5 mL of H 2 O. The organic layer was dried with MgSO 4 , filtered and the solvent is removed under reduced pressure. The residue was purified by flash chromatography using a mixture of CH 2 Cl 2 and MeOH (9:1) and after removal of the solvents a white solid (336 mg, 99%) was obtained. The Ntboc protection group of this solid (130 mg, 0.38 mmol) was cleaved using the general procedure D for 2 h and a clear oil 68 (87 mg, 95%) was obtained after extraction. This oil 68 (87 mg, 0.36 mmol) was transferred to its fumaric acid salt 68F by using the general procedure G with fumaric acid (42 mg, 0.36 mmol). Compound 68F (57 mg, 44%) was obtained as an off white solid in 42% yield over three steps; mp 155-158°C (dec). Compound 66 (296 mg, 1.1 mmol) was dissolved in 2 mL of MeCN and methyl iodide (625 mg, 4.4 mmol) was added. The solution was stirred at rt for 24 h before the volatiles were removed under reduced pressure. The residue was dissolved in 10 mL of CH 2 Cl 2 and Et 3 N (101 mg, 1 mmol) and N-tboc-bispidine 13 (226 mg, 1 mmol) was added. The solution was stirred at rt for another 24 h before it was washed twice with 5 mL of hydrochloric acid (1 M) and once with 5 mL of H 2 O. The organic layer was dried with MgSO 4 , filtered and the solvent was removed under reduced pressure. The residue was purified by flash chromatography using a mixture of CH 2 Cl 2 and MeOH (40:1) and after removal of the solvents a white solid (355 mg, 83%) was obtained. The N-tboc protection group of this solid (300 mg, 0.70 mmol) was cleaved using the general procedure D for 3 h and a clear oil 69 (191 mg, 83%) was obtained after extraction. This oil 69 (124 mg, 0.38 mmol) was transferred to its fumaric acid salt 69F by using the general procedure G with fumaric acid (44 mg, 0.38 mmol). Compound 69F (124 mg, 72%) was obtained as a white solid in 50% yield over three steps; mp 172-175°C (dec). Compound 71 was obtained by using general procedure H with iodoethane (101.4 mg). Purification was achieved by flash chromatography using a mixture of CH 2 Cl 2 and MeOH (9:1) and after removal of the solvents under reduced pressure the final compound 71 was obtained as a clear oil (74.0 mg, 58%). 
Membrane preparation: preparation of rat brains
Frozen rat brains (Pel-Freez Biologicals, AR) (-80°C) were thawed slowly before the preparation of the P2 rat brain membrane fraction (30-60 min. on ice, afterwards at rt). A single cut just behind the inferior colliculi was done to exclude the cerebellum and the medulla. After the determination of the wet weight (1.32 g on average), the brains were pressed into a pulp using a syringe and homogenized in saccharose buffer with a glass teflon homogenizer (potter, 10 sec.). The tissue was then centrifuged (1000g, 20 min., 4°C), the supernatant (S1) aspirated with a Pasteur pipette and stored on ice. The P1 pellet was re-suspended in saccharose buffer and the centrifugation was repeated. The supernatant S1
0 was collected and added to the supernatant S1. The combined supernatants were centrifuged (25,000g, 20 min, 4°C), the supernatant S2 was removed and the pellet P2 collected and diluted with HSS buffer. The buffer volume added was calculated on the basis of the wet weight on a ratio 1:2.
The final pellet was stored in aliquots at À80°C. On the day of the experiment, the P2 membrane fraction was thawed, diluted with HSS buffer (30-fold volume), homogenized and centrifuged (35,000g, 10 min, 4°C) . The collected pellet was suspended in HSS buffer and used in the radioligand binding experiment.
Membrane preparation: preparation of calf adrenals
Frozen calf adrenals (Pel-Freez Biologicals, AR) (À80°C) were placed on ice (30-60 min.) and allowed to thaw slowly before they were cut into small pieces. After determination of the wet weight (4-6 g), the tissue was homogenized in HSS buffer (Ultraturrax at 750 rpm). The homogenate was centrifuged (30,000g, 10 min, 4°C), the pellets collected and washed. This procedure was repeated five times. The buffer volume to re-suspend the pellet was calculated on the basis of the wet weight in a ratio of 1:6.5.
The prepared tissues were stored in aliquots at À80°C. One hour before the experiments the tissues were slowly thawed, homogenized in HSS buffer and centrifuged (25, 000g, 20 min,  4°C) . The pellets were re-suspended in fresh HSS buffer and used for radioligand binding assays.
Membrane preparation: preparation of Torpedo californica electroplax
Frozen samples of Torpedo californica electric organ (Dr. Charles Winkler, CA) (À80°C) were placed on ice (30-60 min.) and allowed to thaw slowly before the membrane preparation. The tissue was homogenized in ice-cold HSS buffer (Ultraturrax at 750 rpm) and centrifuged (30,000g, 10 min, 4°C). The pellets were collected, washed four times with HSS buffer through rehomogenization and centrifugation at the same settings. The remaining pellets were collected, re-suspended in HSS buffer and stored at aliquots at À80°C.
One hour before the experiments the tissues were slowly thawed, homogenized in HSS buffer and centrifuged (25,000g, 20 min, 4°C). The pellets were re-suspended in fresh HSS buffer and used for radioligand binding assays. A dilution row of 6-9 concentrations of the test compound was prepared. Each assay sample, with a total volume of 500 lL contained 100 lL of the membrane protein (60 lg), 100 lL of (±)- 
Two-electrode voltage clamp electrophysiology
Experiments were conducted using OpusXpress 6000A (Molecular Devices, Union City, CA). 60 Both, the voltage and current electrodes were filled with 3 M KCl. Oocytes were voltage-clamped at -60 mV. The oocytes were bath-perfused with Ringer's solution (115 mM NaCl, 2.5 mM KCl, 1.8 mM CaCl 2 , 10 mM HEPES, and 1 lM atropine, pH 7.2) at 2 mL/min for a7 receptors and at 4 mL/ min for other subtypes. To evaluate the effects of different compounds on ACh-evoked responses of various nAChR subtypes expressed in oocytes, baseline conditions were defined by two initial applications of ACh made before co-applications of experimental compounds with the control ACh. The agonist solutions were applied from a 96-well plate via disposable tips, and the test compounds were co-applied with ACh by the OpusXpress pipette delivery system for acute co-application experiments. Drug applications were 12 s in duration followed by a 181-s washout period for a7 receptors and 8 s with a 241-s washout for other subtypes. A typical recording for each oocyte contained two initial control applications of ACh, an experimental compound application, and then a follow-up control application of ACh to determine the desensitization or rundown of the receptors. The control ACh concentrations were: 30 lM for a1b1ed 60 lM for a7, 100 lM for a3b4, 30 lM for a4b2.
Data were collected at 50 Hz, filtered at 20 Hz, analyzed by Clampfit 9.2 (Molecular Devices) and Excel 2003 (Microsoft, Redmond, WA), and normalized to the averaged peak current or net charge response of the two initial ACh controls. 61 Data were expressed as means ± SEM from at least four oocytes for each experiment and plotted by Kaleidagraph 3.0.2 (Abelbeck Software, Reading, PA).
Calculation of physicochemical properties
The physicochemical properties have been calculated using ACD/ADME Suite 5.0 and ACD/PhysChem (ACD/Labs)
